Baseline demographics and clinical characteristics of all analysed SSc patients (N=63)
| Baseline characteristics (N=63) | ||
|---|---|---|
| Age (years) mean±SEM | N=63; 50.9±1.6 | |
| Sex | n | (%) |
| Female | 45 | 71.4 |
| Scleroderma subtype | ||
| Diffuse | 46 | 73.0 |
| Limited | 17 | 27.0 |
| Disease duration in years median (IQR) | N=60; 6 (3–11) | |
| Follow-up in months (IQR) | 7 (4–9) | |
| Autoantibodies positive | n/N | (%) |
| ACA | 3/62 | 4.8 |
| Anti-RNA polymerase III | 3/52 | 5.8 |
| Anti-Scl-70 | 42/61 | 68.9 |
| Anti-U1-snRNP | 2/50 | 4.0 |
Autoantibodies were measured and interpreted according to local standards. Demographics and clinical characteristics are defined according to EUSTAR criteria.30
ACA, anticentromere antibody; anti-Scl 70, antitopoisomerase 1 antibody; anti-U1-snRNP, anti-U1 small nuclear ribonucleoprotein antibody; EUSTAR, European Scleroderma Trial and Research; N, number of patients available for analysis; n, number of patients with the specific feature; SSc, systemic sclerosis.